List of Tables
Table 1. Anti-VEGF Drug Market Trends
Table 2. Anti-VEGF Drug Market Drivers & Opportunity
Table 3. Anti-VEGF Drug Market Challenges
Table 4. Anti-VEGF Drug Market Restraints
Table 5. Global Anti-VEGF Drug Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Anti-VEGF Drug Revenue Market Share by Company (2019-2024)
Table 7. Global Anti-VEGF Drug Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Anti-VEGF Drug Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Anti-VEGF Drug Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Anti-VEGF Drug Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Anti-VEGF Drug Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Anti-VEGF Drug
Table 13. Global Anti-VEGF Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGF Drug as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGF Drug Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Anti-VEGF Drug Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Anti-VEGF Drug Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Anti-VEGF Drug Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Anti-VEGF Drug Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Anti-VEGF Drug Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Anti-VEGF Drug Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Anti-VEGF Drug Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Anti-VEGF Drug Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Anti-VEGF Drug Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Anti-VEGF Drug Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Anti-VEGF Drug Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Anti-VEGF Drug Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Anti-VEGF Drug Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Anti-VEGF Drug Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Anti-VEGF Drug Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Anti-VEGF Drug Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Anti-VEGF Drug Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Anti-VEGF Drug Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Anti-VEGF Drug Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Anti-VEGF Drug Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Anti-VEGF Drug Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Anti-VEGF Drug Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Anti-VEGF Drug Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Anti-VEGF Drug Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Anti-VEGF Drug Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Anti-VEGF Drug Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Anti-VEGF Drug Sales Value by Region (2019-2024) & (%)
Table 44. Global Anti-VEGF Drug Sales Value by Region (2025-2030) & (%)
Table 45. Global Anti-VEGF Drug Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Anti-VEGF Drug Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Anti-VEGF Drug Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Anti-VEGF Drug Sales Volume by Region (2019-2024) & (%)
Table 49. Global Anti-VEGF Drug Sales Volume by Region (2025-2030) & (%)
Table 50. Global Anti-VEGF Drug Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Anti-VEGF Drug Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Anti-VEGF Drug Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Anti-VEGF Drug Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Anti-VEGF Drug Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Anti-VEGF Drug Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Anti-VEGF Drug Sales Volume, (2025-2030) & (K Units)
Table 57. F. Hoffmann-La Roche Ltd Company Information
Table 58. F. Hoffmann-La Roche Ltd Introduction and Business Overview
Table 59. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. F. Hoffmann-La Roche Ltd Anti-VEGF Drug Product Offerings
Table 61. F. Hoffmann-La Roche Ltd Recent Development
Table 62. Amgen Inc Company Information
Table 63. Amgen Inc Introduction and Business Overview
Table 64. Amgen Inc Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Amgen Inc Anti-VEGF Drug Product Offerings
Table 66. Amgen Inc Recent Development
Table 67. Pfizer, Inc Company Information
Table 68. Pfizer, Inc Introduction and Business Overview
Table 69. Pfizer, Inc Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Pfizer, Inc Anti-VEGF Drug Product Offerings
Table 71. Pfizer, Inc Recent Development
Table 72. Xbrane Biopharma AB Company Information
Table 73. Xbrane Biopharma AB Introduction and Business Overview
Table 74. Xbrane Biopharma AB Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Xbrane Biopharma AB Anti-VEGF Drug Product Offerings
Table 76. Xbrane Biopharma AB Recent Development
Table 77. Allergan Company Information
Table 78. Allergan Introduction and Business Overview
Table 79. Allergan Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Allergan Anti-VEGF Drug Product Offerings
Table 81. Allergan Recent Development
Table 82. Bayer AG Company Information
Table 83. Bayer AG Introduction and Business Overview
Table 84. Bayer AG Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Bayer AG Anti-VEGF Drug Product Offerings
Table 86. Bayer AG Recent Development
Table 87. Regeneron Pharmaceuticals Inc. Company Information
Table 88. Regeneron Pharmaceuticals Inc. Introduction and Business Overview
Table 89. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Regeneron Pharmaceuticals Inc. Anti-VEGF Drug Product Offerings
Table 91. Regeneron Pharmaceuticals Inc. Recent Development
Table 92. Viatris Inc Company Information
Table 93. Viatris Inc Introduction and Business Overview
Table 94. Viatris Inc Anti-VEGF Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Viatris Inc Anti-VEGF Drug Product Offerings
Table 96. Viatris Inc Recent Development
Table 97. Key Raw Materials Lists
Table 98. Raw Materials Key Suppliers Lists
Table 99. Anti-VEGF Drug Downstream Customers
Table 100. Anti-VEGF Drug Distributors List
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-VEGF Drug Product Picture
Figure 2. Global Anti-VEGF Drug Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Anti-VEGF Drug Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Anti-VEGF Drug Sales Volume (2019-2030) & (K Units)
Figure 5. Global Anti-VEGF Drug Sales Price (2019-2030) & (US$/Unit)
Figure 6. Anti-VEGF Drug Report Years Considered
Figure 7. Global Anti-VEGF Drug Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Anti-VEGF Drug Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-VEGF Drug Revenue in 2023
Figure 10. Anti-VEGF Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Avastin Picture
Figure 12. Lucentis Picture
Figure 13. Eylea Picture
Figure 14. Global Anti-VEGF Drug Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Anti-VEGF Drug Sales Value Market Share by Type, 2023 & 2030
Figure 16. Global Anti-VEGF Drug Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 17. Global Anti-VEGF Drug Sales Volume Market Share by Type, 2023 & 2030
Figure 18. Global Anti-VEGF Drug Price by Type (2019-2030) & (US$/Unit)
Figure 19. Product Picture of Age-related Macular Degeneration
Figure 20. Product Picture of Macular Edema Following Retinal Vein Occlusion
Figure 21. Product Picture of Diabetic Macular Edema
Figure 22. Product Picture of Diabetic Retinopathy
Figure 23. Global Anti-VEGF Drug Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Anti-VEGF Drug Sales Value Market Share by Application, 2023 & 2030
Figure 25. Global Anti-VEGF Drug Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 26. Global Anti-VEGF Drug Sales Volume Market Share by Application, 2023 & 2030
Figure 27. Global Anti-VEGF Drug Price by Application (2019-2030) & (US$/Unit)
Figure 28. North America Anti-VEGF Drug Sales Value (2019-2030) & (US$ Million)
Figure 29. North America Anti-VEGF Drug Sales Value by Country (%), 2023 VS 2030
Figure 30. Europe Anti-VEGF Drug Sales Value (2019-2030) & (US$ Million)
Figure 31. Europe Anti-VEGF Drug Sales Value by Country (%), 2023 VS 2030
Figure 32. Asia Pacific Anti-VEGF Drug Sales Value (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Anti-VEGF Drug Sales Value by Country (%), 2023 VS 2030
Figure 34. South America Anti-VEGF Drug Sales Value (2019-2030) & (US$ Million)
Figure 35. South America Anti-VEGF Drug Sales Value by Country (%), 2023 VS 2030
Figure 36. Middle East & Africa Anti-VEGF Drug Sales Value (2019-2030) & (US$ Million)
Figure 37. Middle East & Africa Anti-VEGF Drug Sales Value by Country (%), 2023 VS 2030
Figure 38. Key Countries/Regions Anti-VEGF Drug Sales Value (%), (2019-2030)
Figure 39. Key Countries/Regions Anti-VEGF Drug Sales Volume (%), (2019-2030)
Figure 40. United States Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 41. United States Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 42. United States Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 43. Europe Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 44. Europe Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 45. Europe Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 46. China Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 47. China Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 48. China Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 49. Japan Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 50. Japan Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 51. Japan Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 52. South Korea Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 53. South Korea Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 54. South Korea Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 55. Southeast Asia Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 56. Southeast Asia Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 57. Southeast Asia Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 58. India Anti-VEGF Drug Sales Value, (2019-2030) & (US$ Million)
Figure 59. India Anti-VEGF Drug Sales Value by Type (%), 2023 VS 2030
Figure 60. India Anti-VEGF Drug Sales Value by Application (%), 2023 VS 2030
Figure 61. Anti-VEGF Drug Industrial Chain
Figure 62. Anti-VEGF Drug Manufacturing Cost Structure
Figure 63. Channels of Distribution (Direct Sales, and Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
